Protein feeding prior to sleep as a dietary strategy to improve post-exercise recovery and muscle mass in young and elderly men

Protein feeding prior to sleep as a dietary strategy to improve post-exercise recovery and muscle mass in young and elderly men - Protein feeding prior to sleep

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON36991

Enrollment

144

Registered

2013-02-07

Start date

2013-01-01

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

age-related muscle loss sarcopenia

Interventions

The young subjects will consume a testdrink of 400 ml with 0 gram, 30 gram intrinsically labelled casein of 30 gram intrinsically labelled casein + 2.0 g leucin, randomized after exercise or rest, p

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy males Age between 18 and 35, and 65 and 80 BMI

Exclusion criteria

Exclusion criteria: • Glucose intolerance • Milk and/or fat intolerance • Smoking • Diagnosed GI tract diseases • Arthritic conditions • A history of neuromuscular problems • Any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications) • Use of anticoagulants • Participation in exercise program • Hypertension, high blood pressure above 140/90 mmHg • Not participated in any strength training program within the last 3 months

Design outcomes

Primary

Measure	Time frame
The main study endpoint is muscle protein synthesis (MPS) rate. In order to determine the MPS, the following parameters will be measured in blood and muscle tissue: • Plasma phenylalanine, leucin and tyrosine concentration (expressed as µmol/L) • Plasma verrijking van L-[ring-2H5]-pheenylalanine, L-[1-13C]-phenylalanine en L-[ring-1-13C]-KIC (expressed as mole percent excess, MPE) • Muscle protein bound enrichment of L-[ ring-2H5]-phenylalanine,L-[1-13C]leucine and L-[1-13C]-phenylalanine (expressed as MPE) • L-[1-13C]-phenylalanine enrichment of the muscle free amino acid pool (expressed as MPE)	—

Measure

Time frame

The main study endpoint is muscle protein synthesis (MPS) rate. In order to determine the MPS, the following parameters will be measured in blood and muscle tissue: • Plasma phenylalanine, leucin and tyrosine concentration (expressed as µmol/L) • Plasma verrijking van L-[ring-2H5]-pheenylalanine, L-[1-13C]-phenylalanine en L-[ring-1-13C]-KIC (expressed as mole percent excess, MPE) • Muscle protein bound enrichment of L-[ ring-2H5]-phenylalanine,L-[1-13C]leucine and L-[1-13C]-phenylalanine (expressed as MPE) • L-[1-13C]-phenylalanine enrichment of the muscle free amino acid pool (expressed as MPE)

—

Secondary

Measure	Time frame
Secondary endpoints include whole-body protein turnover, and protein digestion and absorption kinetics. The following parameters will be calculated: • Total rate of phenylalanine appearance and disappearance (= protein turnover) • Exogenous phenylalanine rate of appearance • Endogenous phenylalanine rate of appearance (=protein breakdown) • Plasma availability of phenylalanine • Plasma availability of amino acids • Plasma glucose concentration • Plasma insulin concentration • Hunger and satiety • Heartrate • Sleep quality	—

Measure

Time frame

Secondary endpoints include whole-body protein turnover, and protein digestion and absorption kinetics. The following parameters will be calculated: • Total rate of phenylalanine appearance and disappearance (= protein turnover) • Exogenous phenylalanine rate of appearance • Endogenous phenylalanine rate of appearance (=protein breakdown) • Plasma availability of phenylalanine • Plasma availability of amino acids • Plasma glucose concentration • Plasma insulin concentration • Hunger and satiety • Heartrate • Sleep quality

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)